Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 in systemic lupus erythematosus (phase II/III, randomized double-blind study)
CTR20230336Phase 3Active
- Sponsor
- Mabworks Biotech
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Bejescin in systemic lupus erythematosus (SLE), sponsored by Mabworks Biotech. Started Jun 2023; status: active.
02
Drugs
Bejescin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20230336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230336.